It is the most common non-Hodgkin lymphoma in adults, making up 30-58% of all Non-Hodgkin lymphomas. Although the average age of diagnosis is 70, it is rarely seen in children and young adults. The disease usually presents as a rapidly growing nodal or extranodal mass with systemic symptoms. At times, it manifests itself with fever, weight loss, and night sweats.

 

Diagnosis

Excisional lymph node biopsy should be preferred for diagnosis.

You can find the details of staging and treatment

 

Treatment

Chemotherapy and radiotherapy are used. Treatment strategies should be based on the age of the patient, age-appropriate IPI, and applicability of dose-intensive treatment approaches. Special precautions should be taken to avoid tumor lysis syndrome in patients with high tumor burden.

 

 

REFERENCES

1- "A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project". Blood 89(11): 3909–18. 1997.
2- Morton, LM; Wang, SS; Devesa, SS; Hartge, P; Weisenburger, DD; Linet, MS (2006)."Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood107 (1): 265–76.

3- Smith, A; Howell, D; Patmore, R; Jack, A; Roman, E (2011). "Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network". British Journal of Cancer 105 (11): 1684–92.
4- Smith, A; Roman, E; Howell, D; Jones, R; Patmore, R; Jack, A; Haematological Malignancy Research Network (2010). "The Haematological Malignancy Research Network (HMRN): A new information strategy for population based epidemiology and health service research". British Journal of Haematology 148 (5): 739–53.
5- Kumar, V; Abbas, AK; Fausto, N; Aster, JC (28 May 2009). Robbins & Cotran Pathologic Basis of Disease. Elsevier Health Sciences. p. 607.
6- Freeman, AS; Aster, JC (2012). "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma". In Basow, DS. UpToDate. Waltham, MA: UpToDate.
7- Diebold,J.R.Anderson,J.O.Armitage  et  all.Diffuse  LargeB-cell  Lymphoma:A  Clinicopathologic  Analysis  of  444Cases Classified According to the Updated Kiel Classifi-cation.Leukemia&Lymphoma,2002;43:97-104.
8- Sehn, LH; Berry, B; Chhanabhai, M; Fitzgerald, C; Gill, K; Hoskins, P; Klasa, R; Savage, K J; Shenkier, T; Sutherland, J; Gascoyne, RD; Connors, JM (2007). "The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard International Prognostic Index (IPI) for patients with diffuse large B-cell lymphoma treated with R-CHOP". Blood 109 (5): 1857–61.
9- Lister TA, Crowther D, Sutcliffe SB; et al. (November 1989). "Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting". J. Clin. Oncol. 7 (11): 1630–6